Back to search
FDAFDA · Food and drugs·Recall number D-0213-2025

Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01

Published February 5, 2025 · Recall initiated: January 17, 2025

Summary

FDA records drug Class II recall D-0213-2025, published February 5, 2025 and initiated January 17, 2025. Recalling firm: McKesson; Status: Ongoing; Reported quantity: 192 vials; Lot: Lot# 04647349, Exp Date 5/31/2029. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations: Product intended for quarantine was inadvertently distributed.

What to do

Voluntary: Firm initiated · Letter

Get an email if INFLECTRA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
INFLECTRA
Manufacturer
McKesson
Distributor
Nationwide USA
UPC
0300690809014
Lot
Lot# 04647349, Exp Date 5/31/2029
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01 recalled?

Yes. FDA published recall D-0213-2025 on February 5, 2025. Reported hazard: cGMP Deviations: Product intended for quarantine was inadvertently distributed.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: INFLECTRA. UPC: 0300690809014.